ALLMedicine™ Systemic Mastocytosis Center

Sep 30th, 2022 - This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not ade...

Sep 29th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Sep 29th, 2022 - Serum tryptase is a biomarker used to aid in the identification of certain myeloid neoplasms, most notably systemic mastocytosis, where baseline (BST) levels >20 ng/mL are a minor criterion for diagnosis. Whereas clonal myeloid neoplasms are rare,...

Sep 28th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

Sep 28th, 2022 - Systemic mastocytosis (SM) is a rare and underdiagnosed hematologic neoplasm. Detection of the D816V KIT mutation in the bone marrow (BM) is one of the minor criteria for the diagnosis of SM and requires sensitive methods like ASO-qPCR. In patient...

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Sep 30th, 2022 - This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not ade...

Sep 29th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Sep 28th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

Sep 27th, 2022 - Systemic mastocytosis (SM) represents a heterogenous group of disease characterized by abnormal proliferation of mast cells caused by activating mutations in c-Kit receptor; a tyrosine kinase family receptor present in mast cell that control cell ...

Sep 26th, 2022 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

Mar 25th, 2022 - The European Commission has expanded the current indication for avapritinib (Ayvakyt) to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast ...

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Jan 31st, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended to expand the current indication for avapritinib (Ayvakyt) to include use as a single agent in the treatment of adult patients with aggressive sy...

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

Sep 15th, 2021 - SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. It is characterized by the overaccumulation of mast cells (MCs), which can then penetrate such internal organs as bone marrow (BM).¹ Challenges in identification a...